Heparin And Hyperkalemia Exclusive

Heparin is a cornerstone of modern anticoagulation therapy, used extensively for the prevention and treatment of venous thromboembolism, as well as in the management of acute coronary syndromes. Common adverse effects include bleeding, osteoporosis with long-term use, and heparin-induced thrombocytopenia. However, electrolyte disturbances, specifically hyperkalemia, represent a less frequently discussed but potentially life-threatening complication.

While heparin-induced aldosterone suppression can occur in healthy individuals, resulting in only mild, transient hyperkalemia, clinical significance typically arises in patients with compounding risk factors: heparin and hyperkalemia

Heparin-induced hyperkalemia is an under-recognized but clinically significant electrolyte disorder where the administration of heparin—either unfractionated (UFH) or low-molecular-weight (LMWH)—leads to an elevation of serum potassium levels. While common side effects like bleeding or heparin-induced thrombocytopenia (HIT) are widely known, the impact on potassium homeostasis occurs in approximately . Mechanism of Action: The Adrenal Link Heparin is a cornerstone of modern anticoagulation therapy,

| Drug | Hyperkalemia Risk | |------|-------------------| | Unfractionated heparin (UFH) | Moderate–High | | Low molecular weight heparin (LMWH) | Low–Moderate (case reports) | | Fondaparinux | Very low (negligible) | | Direct oral anticoagulants (DOACs) | None | | Warfarin | None | resulting in only mild